Clinical Trial Update: A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Calderasib (MK-1084) in combination with Pembrolizumab (MK-3475) for KRAS G12C mutant non-small cell lung cancer with PD-L1 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Calderasib (MK-1084)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING